Supplemental Online Content

Wang J, Zhou M, Xu JY, Zhou RF, Chen B, Wan Y. Comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing hematopoietic stem cell transplantation: a systematic review and network meta-analysis. *JAMA Netw Open*. 2020;3(10):e2017652. doi:10.1001/jamanetworkopen.2020.17652

This supplemental material has been provided by the authors to give readers additional information about their work.

eAppendix. Search Strategies

#1 ((clinical AND trial)[Title/Abstract] OR clinical trial[Title/Abstract] OR random*[Title/Abstract] OR random allocation[Title/Abstract])

#2 ("fungal infection*"[Title/Abstract] OR aspergillosis[Title/Abstract] OR blastomycosis[Title/Abstract] OR candidiasis[Title/Abstract] OR andidosis[Title/Abstract] OR coccidioidomycosis[Title/Abstract] OR cryptococcosis[Title/Abstract] OR histoplasmosis[Title/Abstract] OR mucormycosis[Title/Abstract] OR zygomycosis[Title/Abstract] OR paracoccidioidomycosis[Title/Abstract] OR "penicillium marneffei"[Title/Abstract] OR sporotrichosis[Title/Abstract] OR hyalohyphomycosis[Title/Abstract] OR fusariosis[Title/Abstract] OR fusarium[Title/Abstract] OR scedosporium[Title/Abstract] OR monosporium[Title/Abstract] OR phaeohyphomycosis[Title/Abstract] OR alternaria[Title/Abstract] OR bipolaris[Title/Abstract] OR curvularia[Title/Abstract] OR exserohilum[Title/Abstract] OR cladophialophora[Title/Abstract] OR xylohypha[Title/Abstract] OR trichosporonosis[Title/Abstract] OR malassezia[Title/Abstract] OR pityrosporum[Title/Abstract] OR pneumocystis[Title/Abstract] OR pneumocystosis[Title/Abstract] OR pseudallescherias[Title/Abstract] OR allescherias[Title/Abstract] OR petriellidium[Title/Abstract])

#3 (antifungal[Title/Abstract] OR "antifungal agent*" OR amphotericin*[Title/Abstract] OR albaconazol*[Title/Abstract] OR UR9825[Title/Abstract] OR UR 9825[Title/Abstract] OR UR-9825[Title/Abstract] OR ketoconazol*[Title/Abstract] OR R41400[Title/Abstract] OR R 41400[Title/Abstract] OR R-41400[Title/Abstract] OR fluconazol*[Title/Abstract] OR UK49858[Title/Abstract] OR UK 49858[Title/Abstract] OR UK-49858[Title/Abstract] OR isavuconazol*[Title/Abstract] OR BAL8557[Title/Abstract] OR BAL 8557[Title/Abstract] OR BAL-8557[Title/Abstract] OR itraconazol*[Title/Abstract] OR R51211[Title/Abstract] OR R 51211[Title/Abstract] OR R-51211[Title/Abstract] OR posaconazol*[Title/Abstract] OR SCH56592[Title/Abstract] OR SCH 56592[Title/Abstract] OR SCH-56592[Title/Abstract] OR ravuconazol*[Title/Abstract] OR BMS207147[Title/Abstract] OR BMS 207147[Title/Abstract] OR BMS-207147[Title/Abstract] OR ER30346[Title/Abstract] OR ER 30346[Title/Abstract] OR ER-30346[Title/Abstract]
OR voriconazol*[Title/Abstract] OR UK109496[Title/Abstract] OR UK 109496[Title/Abstract] OR UK-109496[Title/Abstract] OR aminocandin*[Title/Abstract] OR HMR3270[Title/Abstract] OR HMR 3270[Title/Abstract] OR HMR-3270[Title/Abstract] OR IP960[Title/Abstract] OR IP-960[Title/Abstract] OR IP 960[Title/Abstract] OR anidulafungin*[Title/Abstract] OR LY303366[Title/Abstract] OR LY 303366[Title/Abstract] OR LY-303366[Title/Abstract] OR caspofungin*[Title/Abstract] OR MK0991[Title/Abstract] OR MK 0991[Title/Abstract] OR MK-0991[Title/Abstract] OR L743872[Title/Abstract] OR L 743872[Title/Abstract] OR L-743872[Title/Abstract] OR micafungin*[Title/Abstract] OR FK463[Title/Abstract] OR FK 463[Title/Abstract] OR FK-463[Title/Abstract] OR flucytosin*[Title/Abstract] OR nystatin*[Title/Abstract]))

eFigure 1. PRISMA Flowchart

Identification

Records identified through database searching
(n = 39698)

Additional records identified through other sources
(n = 11)

Screening

Records after duplicates removed
(n = 1027)

Records screened
(n = 1027)

Records excluded
(n = 815)

Eligibility

Full-text articles assessed for eligibility
(n = 212)

Full-text articles excluded, with reasons
(n = 143)
• Not appropriate study type (n=133)
• Not appropriate intervention (n=10)

Included

Studies included in qualitative synthesis
(n = 69)

Studies included in quantitative synthesis (network meta-analysis)
(n =69)

eFigure 2. Quality Assessment

Legend: + = Low risk (green); ? = Some concerns (yellow); ? = High risk (red)

Study	Randomisation process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall bias
1 Akiyama, 1993	Low	Some concerns	Low	Low	Some concerns	Some concerns
2 Annaloro, 1995	Some concerns	Some concerns	Low	Low	Some concerns	Some concerns
3 Benhamou, 1991	Low	Some concerns	Low	Low	Some concerns	Some concerns
4 Bodey, 1994	Some concerns	Low	Low	Low	Some concerns	Some concerns
5 Boogaerts, 2001	Some concerns	Low	Low	Low	Low	Some concerns
6 Brincker, 1978	Some concerns	Some concerns	Low	Low	Some concerns	Some concerns
7 Brincker 1983	Some concerns	Some concerns	Low	Low	Low	Some concerns
8 Chaftari, 2012	Low	Some concerns	Low	Low	Low	Some concerns
9 Chandrasekar, 1994	Some concerns	Some concerns	Low	Low	High	High
10 Choi, 2005	High	Some concerns	Low	Low	Low	High
11 Cornely, 2007	Some concerns	Low	Low	Low	Low	Some concerns
12 Donnelly, 1984	Some concerns	Some concerns	Low	Low	Low	Some concerns
13 Egger, 1995	Low	Some concerns	Low	Low	High	High
14 Ellis, 1994	Some concerns	Some concerns	Low	Low	Low	Some concerns
15 Epstein, 2018	Some concerns	Some concerns	Low	Low	Low	Some concerns
16 Estey, 1984	High	Some concerns	Low	Low	Low	High
17 Fisher, 2019	Low	Some concerns	Low	Low	Low	Some concerns
18 Glasmacher, 2006	Low	Low	Low	Low	Low	Low
19 Goodman, 1992	Low	Some concerns	Low	Low	Low	Some concerns
20 Hansen, 1987	Some concerns	Some concerns	Low	Low	Low	Some concerns
21 Harousseau, 2000	Low	Low	Low	Low	Low	Low
22 Hayashi, 2014	Some concerns	Some concerns	Low	Low	Some concerns	Some concerns
23 Hiemenz, 2005	Some concerns	Some concerns	Low	Low	High	High
24 Hiramatsu, 2008	Some concerns	Low	Low	Low	Low	Some concerns
25 Huang, 2012	Low	Some concerns	Low	Low	High	High
26 Huijgens, 1999	Some concerns	Low	Low	Low	Low	Some concerns
27 Ito, 2007	Low	Some concerns	Low	Low	High	High
28 Kaptan, 2003	Some concerns	Some concerns	Low	Low	High	High
29 Kelsey, 1999	Low	Low	Low	Low	Low	Low
30 Kern, 1998	Some concerns	Some concerns	Low	Low	Low	Some concerns
31 Koh, 2002	Some concerns	Low	Low	Low	Low	Some concerns
32 Lass-Florl, 2003	Some concerns	Some concerns	Low	Low	High	High
33 Mahmoud, 2016	Some concerns	Some concerns	Low	Low	Some concerns	Some concerns
34 Marks, 2011	Low	Low	Low	Low	High	High
35 Marr, 2004	Some concerns	Low	Low	Low	Low	Some concerns
36 Mattiuzzi, 2003	Low	Some concerns	Low	Low	Low	Some concerns
37 Mattiuzzi, 2006	Some concerns	Low	Low	Low	Low	Some concerns
38 Mattiuzzi, 2011	Some concerns	Low	Low	Low	Low	Some concerns
39 Menichetti, 1999	Some concerns	Low	Low	Low	Low	Some concerns
40 Morgenstern, 1999	Low	Some concerns	Low	Low	Low	Some concerns
41 Nucci, 2000	Low	Some concerns	Low	Low	Low	Some concerns
42 Oren 2006	Some concerns	Some concerns	Low	Low	High	High
43 Palmblad, 1992	Some concerns	Some concerns	Low	Low	Low	Some concerns
44 Park, 2016	Some concerns	Some concerns	Low	Low	Low	Some concerns
45 Penack, 2006	Some concerns	High	Low	High	Low	High
46 Perfect, 1992	Some concerns	Some concerns	Low	Low	Low	Some concerns
47 Philpott-Howard, 1993	Some concerns	Low	Low	Low	High	High
48 Rijnders, 2008	Low	Low	Low	Low	Low	Low
49 Riley, 1994	Some concerns	Some concerns	Low	Low	High	High
50 Sawada, 2009	Some concerns	Some concerns	Low	Some concerns	Some concerns	Some concerns
51 Schaffner, 1995	Some concerns	Low	Low	Low	Low	Some concerns
52 Schwartz, 1999	Low	Low	Low	Low	Low	Low
53 Shen, 2013	Some concerns	Some concerns	Low	Low	High	High
54 Slavin, 1995	Some concerns	Low	Low	Low	Low	Some concerns
55 Tollemar, 1993	Some concerns	Some concerns	Low	Some concerns	Low	Some concerns
56 Ullmann, 2007	Some concerns	Low	Low	Low	Low	Some concerns
57 Van Burik, 2004	Some concerns	Low	Low	Low	Low	Some concerns
58 Vehreschild, 2007	Low	Some concerns	Low	Low	High	High
59 Vreugdenhil, 1993	Some concerns	Some concerns	Low	Low	Some concerns	Some concerns
60 Wingard, 1987	Some concerns	Some concerns	Low	Some concerns	Low	Some concerns
61 Wingard, 2010	Some concerns	Low	Low	Low	High	High
62 Winston, 1993	Some concerns	Low	Low	Low	Low	Some concerns
63 Winston, 2003	Low	Low	Low	Low	Low	Low
64 Wolff, 2000	Some concerns	Some concerns	Low	Low	Low	Some concerns
65 Yamac, 1995	Some concerns	Some concerns	Low	Some concerns	Low	Some concerns
66 Young, 1999	Some concerns	Some concerns	Low	Low	Low	Some concerns
67 Behre, 1995	Some concerns	Low	Low	Low	Low	Some concerns
68 Laverdiere, 2000	Some concerns	Some concerns	Low	Low	Low	Some concerns
69 Rotstein, 1999	Some concerns	Low	High	Low	Low	High

© 2020 Wang J et al. *JAMA Netw Open.*

eFigure 3. Network Geometry of All Outcomes

Panel A. Fungal Infections

Legend: the blue nodes represent the interventions compared while the edges represent the direct comparisons available between pairs of interventions. The node sizes are weighted based on the number of patients in each arm while the edges are weighted using inverse variance. The edge colors (green or red) are weighted based on the quality of the studies included. A green edge indicates the comparison with high quality studies while a red line indicates comparison with low quality studies. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel B. IFI

Legend: the blue nodes represent the interventions compared while the edges represent the direct comparisons available between pairs of interventions. The node sizes are weighted based on the number of patients in each arm while the edges are weighted using inverse variance. The edge colors (green or red) are weighted based on the quality of the studies included. A green edge indicates the comparison with high quality studies while a red line indicates comparison with low quality studies. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel C. Proven IFI

Legend: the blue nodes represent the interventions compared while the edges represent the direct comparisons available between pairs of interventions. The node sizes are weighted based on the number of patients in each arm while the edges are weighted using inverse variance. The edge colors (green or red) are weighted based on the quality of the studies included. A green edge indicates the comparison with high quality studies while a red line indicates comparison with low quality studies. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel D.   Invasive Candidiasis

Legend: the blue nodes represent the interventions compared while the edges represent the direct comparisons available between pairs of interventions. The node sizes are weighted based on the number of patients in each arm while the edges are weighted using inverse variance. The edge colors (green or red) are weighted based on the quality of the studies included. A green edge indicates the comparison with high quality studies while a red line indicates comparison with low quality studies. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel E.   Invasive Aspergillus

Legend: the blue nodes represent the interventions compared while the edges represent the direct comparisons available between pairs of interventions. The node sizes are weighted based on the number of patients in each arm while the edges are weighted using inverse variance. The edge colors (green or red) are weighted based on the quality of the studies included. A green edge indicates the comparison with high quality studies while a red line indicates comparison with low quality studies. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel F.   Mortality

Legend: the blue nodes represent the interventions compared while the edges represent the direct comparisons available between pairs of interventions. The node sizes are weighted based on the number of patients in each arm while the edges are weighted using inverse variance. The edge colors (green or red) are weighted based on the quality of the studies included. A green edge indicates the comparison with high quality studies while a red line indicates comparison with low quality studies. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel G.   Fungi-related death

Legend: the blue nodes represent the interventions compared while the edges represent the direct comparisons available between pairs of interventions. The node sizes are weighted based on the number of patients in each arm while the edges are weighted using inverse variance. The edge colors (green or red) are weighted based on the quality of the studies included. A green edge indicates the comparison with high quality studies while a red line indicates comparison with low quality studies. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel H.   Withdrawal

Legend: the blue nodes represent the interventions compared while the edges represent the direct comparisons available between pairs of interventions. The node sizes are weighted based on the number of patients in each arm while the edges are weighted using inverse variance. The edge colors (green or red) are weighted based on the quality of the studies included. A green edge indicates the comparison with high quality studies while a red line indicates comparison with low quality studies. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

eFigure 4. Forest Plots of All Outcomes

Panel A. Fungal Infections

Legend: The results are reported as Relative risks (RRs) and 95% confidence intervals (CIs). The blue line (line of null effect) is equal to 1. The solid black lines represent the CIs while the diamond summarizes the RRs. For each pairwise comparison, the forest plot should be read as following: if the diamond with the entire CI did not reach the blue line of null effect, there is a significant difference. If the entire CI is on the left of the null effect, the event is significantly higher in the "intervention arm" while, when the entire CI is on the right, the event is statistically more frequent in the "reference arm". When the entire CI crosses the line of null effect, the difference between the two procedures compared is not statistically significant. In addition, a red line reports the Predictive Interval (PrI), namely the interval within which the estimate of a future study is expected to be. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel B. IFI

Treatment Effect

Polyene vs Placebo
AMB vs Placebo
AMBL vs Placebo
MICZ vs Placebo
KTCZ vs Placebo
FLCZ vs Placebo
ITCZ vs Placebo
VOCZ vs Placebo
POCZ vs Placebo
CASP vs Placebo
MCFG vs Placebo
AMB vs Polyene
AMBL vs Polyene
MICZ vs Polyene
KTCZ vs Polyene
FLCZ vs Polyene
ITCZ vs Polyene
VOCZ vs Polyene
POCZ vs Polyene
CASP vs Polyene
MCFG vs Polyene
AMBL vs AMB
MICZ vs AMB
KTCZ vs AMB
FLCZ vs AMB
ITCZ vs AMB
VOCZ vs AMB
POCZ vs AMB
CASP vs AMB
MCFG vs AMB
MICZ vs AMBL
KTCZ vs AMBL
FLCZ vs AMBL
ITCZ vs AMBL
VOCZ vs AMBL
POCZ vs AMBL
CASP vs AMBL
MCFG vs AMBL
KTCZ vs MICZ
FLCZ vs MICZ
ITCZ vs MICZ
VOCZ vs MICZ
POCZ vs MICZ
CASP vs MICZ
MCFG vs MICZ
FLCZ vs KTCZ
ITCZ vs KTCZ
VOCZ vs KTCZ
POCZ vs KTCZ
CASP vs KTCZ
MCFG vs KTCZ
ITCZ vs FLCZ
VOCZ vs FLCZ
POCZ vs FLCZ
CASP vs FLCZ
MCFG vs FLCZ
VOCZ vs ITCZ
POCZ vs ITCZ
CASP vs ITCZ
MCFG vs ITCZ
POCZ vs VOCZ
CASP vs VOCZ
MCFG vs VOCZ
CASP vs POCZ
MCFG vs POCZ
MCFG vs CASP

Mean with 95%CI and 95%PrI

1.30 (0.58,2.89) (0.48,3.51)
0.65 (0.35,1.20) (0.28,1.51)
0.44 (0.26,0.74) (0.20,0.95)
0.47 (0.10,2.28) (0.08,2.63)
1.08 (0.11,10.58) (0.10,12.16)
1.35 (0.32,5.73) (0.27,8.64)
0.92 (0.41,2.07) (0.34,2.52)
0.54 (0.08,3.70) (0.07,4.25)
0.57 (0.41,0.79) (0.30,1.10)
0.74 (0.30,1.83) (0.25,2.18)
0.58 (0.30,1.10) (0.24,1.38)
0.50 (0.18,1.37) (0.15,1.63)
0.34 (0.13,0.87) (0.11,1.04)
0.36 (0.06,2.13) (0.05,2.45)
1.04 (0.25,4.44) (0.17,6.27)
0.44 (0.21,0.92) (0.17,1.13)
0.57 (0.23,1.42) (0.19,1.70)
0.58 (0.10,3.44) (0.08,3.96)
0.06 (0.00,1.47) (0.00,1.70)
0.16 (0.04,0.57) (0.04,0.67)
0.19 (0.03,1.13) (0.03,1.30)
0.68 (0.31,1.51) (0.25,1.84)
0.72 (0.13,3.94) (0.12,4.54)
2.08 (0.43,10.01) (0.37,11.56)
0.88 (0.44,1.76) (0.36,2.18)
1.14 (0.53,2.42) (0.43,2.97)
1.16 (0.21,6.37) (0.18,7.33)
0.12 (0.01,2.82) (0.00,3.27)
0.31 (0.09,1.14) (0.08,1.30)
0.39 (0.07,2.09) (0.06,2.40)
1.06 (0.20,5.61) (0.18,6.47)
3.06 (0.66,14.21) (0.57,16.43)
1.30 (0.72,2.33) (0.57,2.96)
1.67 (0.85,3.30) (0.68,4.10)
1.70 (0.32,9.06) (0.28,10.45)
0.18 (0.01,3.11) (0.01,4.33)
0.46 (0.14,1.55) (0.12,1.82)
0.57 (0.11,2.97) (0.09,3.42)
2.87 (0.34,24.48) (0.29,28.11)
1.22 (0.24,6.12) (0.21,7.07)
1.57 (0.30,8.10) (0.26,9.34)
1.60 (0.17,15.06) (0.15,17.30)
0.17 (0.00,15.39) (0.00,6.28)
0.43 (0.06,3.00) (0.05,3.44)
0.53 (0.06,4.95) (0.05,5.69)
1.35 (0.19,1.87) (0.08,3.27)
0.55 (0.12,2.49) (0.10,2.88)
0.56 (0.06,4.79) (0.06,5.50)
0.06 (0.00,1.77) (0.00,2.06)
0.15 (0.02,0.94) (0.02,1.08)
0.19 (0.02,1.58) (0.02,1.81)
1.29 (0.24,2.23) (0.58,2.86)
1.31 (0.26,6.65) (0.22,7.67)
0.14 (0.01,3.05) (0.01,3.53)
0.36 (0.12,1.03) (0.10,1.22)
0.44 (0.06,2.18) (0.05,2.51)
1.02 (0.20,5.31) (0.17,6.12)
0.11 (0.00,2.41) (0.00,2.80)
0.28 (0.08,0.91) (0.07,1.07)
0.34 (0.07,1.74) (0.06,2.01)
0.11 (0.00,3.39) (0.00,3.95)
0.27 (0.04,1.89) (0.03,2.17)
0.33 (0.04,3.13) (0.03,3.59)
2.54 (0.10,66.10) (0.08,76.84)
3.12 (0.10,98.03) (0.09,114.37)
1.23 (0.18,8.43) (0.16,9.68)

0   0   1   6.7   110

Legend: The results are reported as Relative risks (RRs) and 95% confidence intervals (CIs). The blue line (line of null effect) is equal to 1. The solid black lines represent the CIs while the diamond summarizes the RRs. For each pairwise comparison, the forest plot should be read as following: if the diamond with the entire CI did not reach the blue line of null effect, there is a significant difference. If the entire CI is on the left of the null effect, the event is significantly higher in the "intervention arm" while, when the entire CI is on the right, the event is statistically more frequent in the "reference arm". When the entire CI crosses the line of null effect, the difference between the two procedures compared is not statistically significant. In addition, a red line reports the Predictive Interval (PrI), namely the interval within which the estimate of a future study is expected to be. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel C. Proven IFI

Legend: The results are reported as Relative risks (RRs) and 95% confidence intervals (CIs). The blue line (line of null effect) is equal to 1. The solid black lines represent the CIs while the diamond summarizes the RRs. For each pairwise comparison, the forest plot should be read as following: if the diamond with the entire CI did not reach the blue line of null effect, there is a significant difference. If the entire CI is on the left of the null effect, the event is significantly higher in the "intervention arm" while, when the entire CI is on the right, the event is statistically more frequent in the "reference arm". When the entire CI crosses the line of null effect, the difference between the two procedures compared is not statistically significant. In addition, a red line reports the Predictive Interval (PrI), namely the interval within which the estimate of a future study is expected to be. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel D. Invasive Candidiasis

Legend: The results are reported as Relative risks (RRs) and 95% confidence intervals (CIs). The blue line (line of null effect) is equal to 1. The solid black lines represent the CIs while the diamond summarizes the RRs. For each pairwise comparison, the forest plot should be read as following: if the diamond with the entire CI did not reach the blue line of null effect, there is a significant difference. If the entire CI is on the left of the null effect, the event is significantly higher in the "intervention arm" while, when the entire CI is on the right, the event is statistically more frequent in the "reference arm". When the entire CI crosses the line of null effect, the difference between the two procedures compared is not statistically significant. In addition, a red line reports the Predictive Interval (PrI), namely the interval within which the estimate of a future study is expected to be. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel E. Invasive Aspergillus

Legend: The results are reported as Relative risks (RRs) and 95% confidence intervals (CIs). The blue line (line of null effect) is equal to 1. The solid black lines represent the CIs while the diamond summarizes the RRs. For each pairwise comparison, the forest plot should be read as following: if the diamond with the entire CI did not reach the blue line of null effect, there is a significant difference. If the entire CI is on the left of the null effect, the event is significantly higher in the "intervention arm" while, when the entire CI is on the right, the event is statistically more frequent in the "reference arm". When the entire CI crosses the line of null effect, the difference between the two procedures compared is not statistically significant. In addition, a red line reports the Predictive Interval (PrI), namely the interval within which the estimate of a future study is expected to be. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel F.   Mortality

Legend: The results are reported as Relative risks (RRs) and 95% confidence intervals (CIs). The blue line (line of null effect) is equal to 1. The solid black lines represent the CIs while the diamond summarizes the RRs. For each pairwise comparison, the forest plot should be read as following: if the diamond with the entire CI did not reach the blue line of null effect, there is a significant difference. If the entire CI is on the left of the null effect, the event is significantly higher in the "intervention arm" while, when the entire CI is on the right, the event is statistically more frequent in the "reference arm". When the entire CI crosses the line of null effect, the difference between the two procedures compared is not statistically significant. In addition, a red line reports the Predictive Interval (PrI), namely the interval within which the estimate of a future study is expected to be. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel G. Fungi-related death

Legend: The results are reported as Relative risks (RRs) and 95% confidence intervals (CIs). The blue line (line of null effect) is equal to 1. The solid black lines represent the CIs while the diamond summarizes the RRs. For each pairwise comparison, the forest plot should be read as following: if the diamond with the entire CI did not reach the blue line of null effect, there is a significant difference. If the entire CI is on the left of the null effect, the event is significantly higher in the "intervention arm" while, when the entire CI is on the right, the event is statistically more frequent in the "reference arm". When the entire CI crosses the line of null effect, the difference between the two procedures compared is not statistically significant. In addition, a red line reports the Predictive Interval (PrI), namely the interval within which the estimate of a future study is expected to be. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel H. Withdrawal

Treatment Effect	Mean with 95%CI and 95%PrI
Polyene vs Placebo	0.39 (0.05,3.04) (0.04,3.81)
AMB vs Placebo	1.06 (0.02,53.06) (0.02,71.07)
AMBL vs Placebo	8.96 (2.30,34.92) (1.83,43.94)
KTCZ vs Placebo	0.59 (0.13,2.62) (0.11,3.29)
FLCZ vs Placebo	2.24 (0.03,148.09) (0.02,201.03)
ITCZ vs Placebo	6.92 (0.89,54.07) (0.71,67.73)
VOCZ vs Placebo	0.68 (0.26,1.78) (0.20,2.30)
POCZ vs Placebo	0.81 (0.01,44.57) (0.01,59.96)
CASP vs Placebo	1.22 (0.36,4.20) (0.28,5.31)
MCFG vs Placebo	1.20 (0.63,2.30) (0.46,3.14)
AMB vs Polyene	2.70 (0.03,225.20) (0.02,309.24)
AMBL vs Polyene	22.95 (1.96,269.09) (1.55,340.07)
KTCZ vs Polyene	1.52 (0.12,19.17) (0.09,24.28)
FLCZ vs Polyene	1.73 (0.28,10.56) (0.23,13.20)
ITCZ vs Polyene	3.08 (0.36,26.43) (0.29,33.16)
VOCZ vs Polyene	0.90 (0.12,6.69) (0.10,8.37)
POCZ vs Polyene	11.07 (0.82,150.44) (0.64,190.96)
CASP vs Polyene	1.31 (0.10,16.40) (0.08,20.76)
MCFG vs Polyene	1.09 (0.15,7.68) (0.12,9.61)
AMBL vs AMB	8.49 (0.13,536.65) (0.10,726.88)
KTCZ vs AMB	0.56 (0.01,37.08) (0.01,50.33)
FLCZ vs AMB	0.64 (0.01,36.21) (0.01,48.78)
ITCZ vs AMB	1.14 (0.02,60.38) (0.02,81.09)
VOCZ vs AMB	0.33 (0.01,20.60) (0.00,27.88)
POCZ vs AMB	4.10 (0.06,283.07) (0.04,385.10)
CASP vs AMB	0.48 (0.01,31.90) (0.01,43.30)
MCFG vs AMB	0.40 (0.01,24.33) (0.00,32.88)
KTCZ vs AMBL	0.07 (0.01,0.50) (0.01,0.62)
FLCZ vs AMBL	0.08 (0.01,0.40) (0.01,0.50)
ITCZ vs AMBL	0.13 (0.03,0.61) (0.02,0.76)
VOCZ vs AMBL	0.04 (0.01,0.26) (0.00,0.32)
POCZ vs AMBL	0.48 (0.20,1.14) (0.16,1.50)
CASP vs AMBL	0.06 (0.01,0.43) (0.01,0.53)
MCFG vs AMBL	0.05 (0.01,0.29) (0.01,0.37)
FLCZ vs KTCZ	1.14 (0.19,6.73) (0.15,8.41)
ITCZ vs KTCZ	2.03 (0.40,10.32) (0.32,12.90)
VOCZ vs KTCZ	0.59 (0.08,4.27) (0.07,5.35)
POCZ vs KTCZ	7.29 (0.81,65.36) (0.65,82.07)
CASP vs KTCZ	0.86 (0.11,7.04) (0.08,8.83)
MCFG vs KTCZ	0.72 (0.11,4.88) (0.08,6.10)
ITCZ vs FLCZ	1.78 (0.55,5.71) (0.44,7.25)
VOCZ vs FLCZ	0.52 (0.22,1.24) (0.17,1.62)
POCZ vs FLCZ	6.40 (0.98,41.93) (0.78,52.42)
CASP vs FLCZ	0.76 (0.13,4.43) (0.10,5.53)
MCFG vs FLCZ	0.63 (0.30,1.31) (0.23,1.75)
VOCZ vs ITCZ	0.29 (0.07,1.25) (0.05,1.57)
POCZ vs ITCZ	3.60 (0.63,20.45) (0.51,25.56)
CASP vs ITCZ	0.43 (0.11,1.60) (0.09,2.02)
MCFG vs ITCZ	0.35 (0.09,1.41) (0.07,1.77)
POCZ vs VOCZ	12.34 (1.55,98.14) (1.24,122.96)
CASP vs VOCZ	1.46 (0.20,10.48) (0.16,13.11)
MCFG vs VOCZ	1.21 (0.39,3.80) (0.30,4.83)
CASP vs POCZ	0.12 (0.01,1.05) (0.01,1.32)
MCFG vs POCZ	0.10 (0.01,0.74) (0.01,0.93)
MCFG vs CASP	0.83 (0.12,5.64) (0.10,7.05)

0   .1   1   37   735

Legend: The results are reported as Relative risks (RRs) and 95% confidence intervals (CIs). The blue line (line of null effect) is equal to 1. The solid black lines represent the CIs while the diamond summarizes the RRs. For each pairwise comparison, the forest plot should be read as following: if the diamond with the entire CI did not reach the blue line of null effect, there is a significant difference. If the entire CI is on the left of the null effect, the event is significantly higher in the "intervention arm" while, when the entire CI is on the right, the event is statistically more frequent in the "reference arm". When the entire CI crosses the line of null effect, the difference between the two procedures compared is not statistically significant. In addition, a red line reports the Predictive Interval (PrI), namely the interval within which the estimate of a future study is expected to be. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel A. Fungal Infections

Placebo											
0.51 (**0.27,0.97**)	MCFG										
0.59 (0.24,1.40)	0.68 (0.09,4.89)	CASP									
0.48 (**0.35,0.64**)	0.38 (0.01,12.17)	0.56 (0.02,14.92)	POCZ								
1.14 (0.19,6.74)	3.00 (0.30,29.57)	4.44 (0.60,32.58)	7.95 (0.24,258.87)	VOCZ							
1.06 (0.50,2.22)	2.77 (0.52,14.76)	**4.09** (**1.18,14.17**)	7.34 (0.33,165.09)	0.92 (0.17,5.01)	ITCZ						
0.42 (0.23,0.77)	1.90 (0.37,9.75)	2.81 (0.92,8.57)	5.04 (0.23,111.00)	0.63 (0.12,3.31)	0.69 (0.40,1.19)	FLCZ					
3.51 (0.85,14.50)	1.68 (0.30,9.36)	2.48 (0.68,9.10)	4.45 (0.19,102.44)	0.56 (0.10,3.17)	0.61 (0.28,1.30)	0.88 (0.45,1.72)	KTCZ				
0.23 (**0.06,0.79**)	0.91 (0.12,6.95)	1.34 (0.24,7.34)	2.40 (0.09,66.64)	0.30 (0.04,2.35)	0.33 (0.09,1.24)	0.48 (0.13,1.72)	0.54 (0.13,2.16)	MICZ			
0.52 (**0.32,0.83**)	2.07 (0.39,11.09)	3.07 (0.89,10.63)	5.50 (0.26,115.32)	0.69 (0.13,3.76)	0.75 (0.39,1.45)	1.09 (0.63,1.89)	1.23 (0.58,2.63)	2.29 (0.60,8.73)	AMBL		
0.59 (**0.34,1.00**)	2.35 (0.43,12.77)	3.47 (0.97,12.35)	6.22 (0.27,141.48)	0.78 (0.14,4.33)	0.85 (0.42,1.72)	1.23 (0.67,2.27)	1.40 (0.63,3.12)	2.59 (0.66,10.10)	1.13 (0.56,2.30)	AMB	
0.71 (0.42,1.20)	2.83 (0.52,15.36)	**4.18** (**1.26,13.85**)	7.49 (0.33,170.31)	0.94 (0.17,5.21)	1.02 (0.51,2.06)	1.49 (0.96,2.31)	1.68 (0.76,3.74)	3.12 (0.80,12.14)	1.36 (0.67,2.76)	1.21 (0.57,2.55)	Polyene

Legend: RR >1 means the treatment in top left is better. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel B. IFI

Placebo											
0.58 (0.30,1.10)	**MCFG**										
0.74 (0.30,1.83)	0.81 (0.12,5.59)	**CASP**									
0.57 (0.42,0.79)	0.32 (0.01,10.07)	0.39 (0.02,10.24)	**POCZ**								
0.54 (0.08,3.70)	3.00 (0.32,28.14)	3.68 (0.53,25.67)	9.36 (0.30,296.64)	**VOCZ**							
0.92 (0.41,2.07)	2.95 (0.58,15.10)	**3.62 (1.09,11.98)**	9.19 (0.41,204.06)	0.98 (0.19,5.13)	**ITCZ**						
1.35 (0.32,5.73)	2.29 (0.46,11.41)	2.81 (0.97,8.14)	7.14 (0.33,155.48)	0.76 (0.15,3.87)	0.78 (0.45,1.35)	**FLCZ**					
1.08 (0.11,10.58)	5.39 (0.63,45.72)	**6.62 (1.07,41.06)**	16.81 (0.57,499.89)	1.80 (0.21,15.45)	1.83 (0.40,8.30)	2.35 (0.53,10.38)	**KTCZ**				
0.47 (0.10,2.28)	1.88 (0.20,17.45)	2.30 (0.33,15.91)	5.85 (0.19,184.60)	0.63 (0.07,5.89)	0.64 (0.12,3.28)	0.82 (0.16,4.11)	0.35 (0.04,2.97)	**MICZ**			
0.44 (0.26,0.74)	1.76 (0.34,9.22)	2.16 (0.64,7.28)	5.50 (0.27,113.20)	0.59 (0.11,3.13)	0.60 (0.30,1.18)	0.77 (0.43,1.38)	0.33 (0.07,1.52)	0.94 (0.18,4.95)	**AMBL**		
0.65 (0.35,1.20)	2.60 (0.48,14.05)	3.19 (0.90,11.32)	8.10 (0.35,184.78)	0.87 (0.16,4.77)	0.88 (0.41,1.88)	1.13 (0.57,2.26)	0.48 (0.10,2.32)	1.38 (0.25,7.54)	1.47 (0.66,3.26)	**AMB**	
1.30 (0.58,2.89)	5.18 (0.89,30.29)	**6.37 (1.75,23.18)**	16.17 (0.68,383.87)	1.73 (0.29,10.27)	1.76 (0.70,4.39)	**2.26 (1.09,4.72)**	0.96 (0.18,5.04)	2.76 (0.47,16.25)	**2.94 (1.15,7.52)**	2.00 (0.73,5.46)	**Polyene**

Legend: RR >1 means the treatment in top left is better. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel C. Proven IFI

Placebo											
0.17 (0.05,0.58)	MCFG										
0.65 (0.36,1.16)	3.61 (0.69,18.75)	CASP									
0.36 (0.15,0.85)	0.47 (0.01,20.66)	0.13 (0.00,6.31)	POCZ								
2.63 (0.24,28.52)	0.80 (0.19,3.46)	0.22 (0.04,1.34)	1.70 (0.04,79.09)	VOCZ							
0.32 (0.21,0.48)	3.03 (0.96,9.57)	0.84 (0.26,2.72)	6.39 (0.16,255.44)	3.76 (0.97,14.58)	ITCZ						
7.86 (0.75,82.43)	1.50 (0.61,3.69)	0.41 (0.10,1.65)	3.16 (0.08,123.47)	1.86 (0.59,5.87)	0.49 (0.24,1.01)	FLCZ					
7.96 (0.41,154.32)	37.33 (1.64,850.80)	10.34 (0.40,265.04)	78.77 (0.72,8627.55)	46.42 (1.88,1145.92)	12.34 (0.60,253.24)	24.94 (1.25,497.77)	KTCZ				
NA	NA	NA	NA	NA	NA	NA	NA	MICZ			
0.33 (0.06,2.02)	1.56 (0.20,12.22)	0.43 (0.05,4.03)	3.30 (0.14,78.29)	1.94 (0.22,17.12)	0.52 (0.08,3.43)	1.04 (0.16,6.63)	0.04 (0.00,1.34)	NA	AMBL		
2.73 (0.30,25.04)	12.81 (1.13,145.20)	3.55 (0.27,46.70)	27.02 (0.38,1919.88)	15.92 (1.27,199.94)	4.23 (0.43,41.87)	8.56 (0.90,81.56)	0.34 (0.01,13.89)	NA	8.19 (0.47,142.23)	AMB	
0.68 (0.27,1.73)	3.20 (0.94,10.91)	0.89 (0.18,4.44)	6.74 (0.16,289.39)	3.97 (0.96,16.40)	1.06 (0.35,3.17)	2.14 (0.93,4.90)	0.09 (0.00,1.91)	NA	2.04 (0.27,15.50)	0.25 (0.02,2.76)	Polyene

Legend: RR >1 means the treatment in top left is better. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel D. Invasive Candidiasis

Placebo											
0.44 (0.02,11.11)	**MCFG**										
0.37 (0.10,1.42)	0.29 (0.03,2.41)	**CASP**									
3.04 (0.51,18.11)	0.80 (0.10,6.53)	2.74 (0.28,27.22)	**POCZ**								
0.15 (0.09,0.26)	0.70 (0.09,5.62)	2.40 (0.25,23.43)	0.87 (0.09,8.44)	**VOCZ**							
0.75 (0.04,13.76)	1.33 (0.23,7.71)	4.59 (0.63,33.22)	1.67 (0.23,11.94)	1.91 (0.27,13.42)	**ITCZ**						
12.52 (2.92,53.66)	0.72 (0.19,2.78)	2.48 (0.49,12.67)	0.90 (0.18,4.54)	1.03 (0.21,5.08)	0.54 (0.18,1.66)	**FLCZ**					
0.59 (0.21,1.62)	2.73 (0.47,15.99)	**9.41 (1.29,68.78)**	3.43 (0.48,24.73)	3.92 (0.55,27.79)	2.05 (0.49,8.51)	**3.79 (1.21,11.85)**	**KTCZ**				
0.18 (0.03,1.03)	0.86 (0.09,8.16)	2.97 (0.26,33.62)	1.08 (0.10,12.12)	1.24 (0.11,13.66)	0.65 (0.09,4.73)	0.65 (0.09,4.73)	0.32 (0.04,2.33)	**MICZ**			
0.33 (0.06,1.98)	1.56 (0.16,15.41)	5.37 (0.46,63.28)	1.96 (0.17,22.81)	2.24 (0.19,25.72)	1.17 (0.15,8.98)	2.16 (0.34,13.78)	0.57 (0.07,4.42)	1.81 (0.15,21.44)	**AMBL**		
1.73 (0.57,5.30)	**8.06 (1.29,50.27)**	**27.82 (3.60,214.81)**	**10.14 (1.33,77.27)**	**11.60 (1.55,86.85)**	**6.07 (1.36,27.14)**	**11.21 (3.27,38.47)**	2.96 (0.65,13.39)	**9.36 (1.20,72.88)**	5.18 (0.63,42.30)	**AMB**	
0.48 (0.17,1.38)	2.25 (0.44,11.53)	**7.78 (1.20,50.40)**	2.83 (0.44,18.11)	3.24 (0.52,20.32)	1.70 (0.40,7.21)	**3.13 (1.26,7.82)**	0.83 (0.19,3.56)	2.62 (0.35,19.64)	1.45 (0.18,11.41)	0.28 (0.06,1.30)	**Polyene**

Legend: RR >1 means the treatment in top left is better. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel E. Invasive Aspergillus

Placebo											
1.22 (0.27,5.59)	MCFG										
0.78 (0.23,2.63)	0.46 (0.03,6.12)	CASP									
0.23 (0.02,2.89)	0.34 (0.04,2.80)	0.73 (0.06,9.37)	POCZ								
1.47 (0.71,3.04)	1.63 (0.29,9.16)	3.56 (0.38,33.18)	4.86 (0.92,25.74)	VOCZ							
2.53 (0.04,181.40)	3.60 (0.52,24.74)	7.84 (0.72,85.87)	**10.72 (1.64,69.97)**	2.20 (0.54,9.06)	ITCZ						
0.23 (0.03,1.86)	3.19 (0.69,14.75)	6.95 (0.86,56.04)	**9.50 (2.19,41.14)**	1.95 (0.88,4.31)	0.89 (0.27,2.86)	FLCZ					
0.38 (0.02,9.10)	0.82 (0.02,30.19)	1.79 (0.04,86.11)	2.45 (0.07,87.51)	0.50 (0.02,14.44)	0.23 (0.01,6.25)	0.26 (0.01,6.73)	KTCZ				
1.00 (0.07,14.55)	2.17 (0.09,51.66)	4.73 (0.15,152.38)	6.47 (0.28,149.16)	1.33 (0.07,23.82)	0.60 (0.04,10.24)	0.68 (0.04,10.92)	2.64 (0.04,168.36)	MICZ			
1.19 (0.08,18.65)	2.58 (0.10,65.43)	5.61 (0.16,191.94)	7.68 (0.31,189.06)	1.58 (0.08,30.36)	0.72 (0.04,13.06)	0.81 (0.05,13.95)	3.13 (0.05,210.02)	1.19 (0.03,55.31)	AMBL		
0.38 (0.10,1.46)	0.83 (0.10,7.23)	1.82 (0.14,24.08)	2.49 (0.30,20.57)	0.51 (0.09,2.84)	0.23 (0.05,1.17)	0.26 (0.06,1.20)	1.01 (0.03,31.89)	**0.38 (0.02,7.67)**	0.32 (0.02,6.92)	AMB	
2.25 (0.44,11.40)	4.88 (0.59,40.27)	10.62 (0.83,135.19)	**14.53 (1.85,114.41)**	2.99 (0.57,15.62)	1.36 (0.21,8.76)	1.53 (0.36,6.54)	5.92 (0.17,210.28)	2.25 (0.10,51.47)	1.89 (0.08,46.33)	5.84 (0.71,47.83)	Polyene

Legend: RR >1 means the treatment in top left is better. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

© 2020 Wang J et al. *JAMA Netw Open.*

Panel F. Mortality

| Placebo											
1.00 (0.56,1.78)	MCFG										
1.11 (0.48,2.56)	0.14 (0.01,3.24)	CASP									
1.17 (0.88,1.56)	0.17 (0.01,3.20)	1.17 (0.33,4.09)	POCZ								
1.48 (0.41,5.32)	0.38 (0.01,23.89)	2.65 (0.11,62.57)	2.27 (0.11,45.57)	VOCZ							
0.96 (0.50,1.87)	0.12 (0.01,2.31)	0.85 (0.30,2.43)	0.73 (0.36,1.46)	0.32 (0.02,6.36)	ITCZ						
0.60 (0.23,1.57)	0.13 (0.01,2.39)	0.90 (0.28,2.91)	0.77 (0.49,1.21)	0.34 (0.02,6.60)	1.06 (0.62,1.80)	FLCZ					
1.58 (0.09,29.16)	0.07 (0.00,1.41)	0.46 (0.10,2.05)	0.40 (0.13,1.19)	0.17 (0.01,3.88)	0.54 (0.19,1.57)	0.51 (0.19,1.40)	KTCZ				
1.06 (0.36,3.09)	0.12 (0.01,2.59)	0.82 (0.17,3.90)	0.70 (0.21,2.32)	0.31 (0.01,7.12)	0.96 (0.30,3.06)	0.91 (0.30,2.75)	1.77 (0.42,7.49)	MICZ			
1.45 (0.62,3.39)	0.16 (0.01,3.30)	1.12 (0.27,4.62)	0.96 (0.35,2.61)	0.42 (0.02,9.09)	1.31 (0.50,3.43)	1.24 (0.51,3.04)	2.42 (0.67,8.78)	1.37 (0.35,5.37)	AMBL		
1.06 (0.65,1.71)	0.12 (0.01,2.22)	0.81 (0.24,2.81)	0.70 (0.34,1.43)	0.31 (0.02,6.11)	0.96 (0.49,1.85)	0.90 (0.52,1.57)	1.77 (0.60,5.21)	1.00 (0.31,3.23)	0.73 (0.27,1.94)	AMB	
0.65 (0.33,1.27)	0.07 (0.00,1.41)	0.50 (0.13,1.87)	0.43 (0.20,0.91)	0.19 (0.01,3.89)	0.59 (0.26,1.31)	0.56 (0.30,1.01)	1.09 (0.34,3.51)	0.61 (0.17,2.16)	0.45 (0.15,1.32)	0.62 (0.27,1.39)	Polyene

Legend: RR >1 means the treatment in top left is better. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel G. Fungi-related death

Placebo											
0.61 (0.20,1.83)	**MCFG**										
0.88 (0.18,4.34)	3.28 (0.08,137.15)	**CASP**									
0.68 (0.40,1.15)	1.00 (0.03,30.18)	0.30 (0.03,3.12)	**POCZ**								
0.46 (0.02,9.94)	0.63 (0.01,61.12)	0.19 (0.00,7.38)	0.63 (0.02,21.34)	**VOCZ**							
2.03 (0.51,8.14)	2.57 (0.10,68.42)	0.78 (0.13,4.63)	2.57 (0.57,11.52)	4.08 (0.17,98.63)	**ITCZ**						
7.96 (0.42,151.37)	2.03 (0.08,50.60)	0.62 (0.08,4.74)	2.03 (0.66,6.21)	3.22 (0.11,90.67)	0.79 (0.29,2.14)	**FLCZ**					
0.18 (0.00,10.92)	23.88 (0.31,1811.79)	7.28 (0.21,251.17)	23.88 (0.98,583.79)	37.90 (0.46,3148.74)	9.30 (0.43,198.93)	11.78 (0.59,235.20)	**KTCZ**				
0.56 (0.12,2.64)	1.67 (0.05,57.18)	0.51 (0.04,6.23)	1.67 (0.23,12.22)	2.65 (0.07,101.19)	0.65 (0.11,3.80)	0.82 (0.16,4.27)	0.07 (0.00,1.95)	**MICZ**			
0.30 (0.09,1.03)	0.90 (0.03,26.97)	0.27 (0.03,2.79)	0.90 (0.16,5.16)	1.42 (0.04,48.12)	0.35 (0.08,1.56)	0.44 (0.12,1.70)	**0.04 (0.00,0.91)**	0.54 (0.07,3.92)	**AMBL**		
1.27 (0.48,3.37)	3.82 (0.14,105.52)	1.16 (0.13,10.46)	3.82 (0.79,18.52)	6.06 (0.19,188.47)	1.49 (0.41,5.40)	1.88 (0.62,5.73)	0.16 (0.01,3.56)	2.29 (0.36,14.33)	4.26 (0.89,20.50)	**AMB**	
1.69 (0.39,7.23)	5.06 (0.15,166.06)	1.54 (0.13,17.73)	5.06 (0.87,29.34)	8.03 (0.22,293.90)	1.97 (0.37,10.52)	2.50 (0.65,9.67)	2.50 (0.65,9.67)	3.03 (0.36,25.36).76)	5.65 (0.83,38.28)	1.33 (0.23,7.65)	**Polyene**

Legend: RR >1 means the treatment in top left is better. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

Panel H. Withdrawal

Placebo											
1.20 (0.63,2.30)	**MCFG**										
1.22 (0.36,4.20)	1.20 (0.18,8.17)	**CASP**									
0.81 (0.01,44.57)	**10.17 (1.35,76.52)**	8.45 (0.95,75.15)	**POCZ**								
0.68 (0.26,1.78)	0.82 (0.26,2.58)	0.68 (0.10,4.91)	0.08 (0.01,0.64)	**VOCZ**							
6.92 (0.89,54.07)	2.83 (0.71,11.25)	2.35 (0.62,8.84)	0.28 (0.05,1.58)	3.43 (0.80,14.73)	**ITCZ**						
2.24 (0.03,148.09)	1.59 (0.76,3.31)	1.32 (0.23,7.72)	0.16 (0.02,1.02)	1.93 (0.81,4.62)	0.56 (0.18,1.81)	**FLCZ**					
0.59 (0.13,2.62)	1.39 (0.20,9.49)	1.16 (0.14,9.45)	0.14 (0.02,1.23)	1.69 (0.23,12.24)	0.49 (0.10,2.51)	0.88 (0.15,5.18)	**KTCZ**				
NA	NA	NA	NA	NA	NA	NA	NA	**MICZ**			
8.96 (2.30,34.92)	**21.08 (3.40,130.57)**	**17.50 (2.35,130.35)**	2.07 (0.87,4.92)	**25.58 (3.89,168.42)**	**7.46 (1.65,33.67)**	**13.26 (2.50,70.41)**	**15.11 (2.01,113.45)**	NA	**AMBL**		
1.06 (0.02,53.06)	2.48 (0.04,150.01)	2.06 (0.03,135.71)	0.24 (0.00,16.88)	3.01 (0.05,187.18)	0.88 (0.02,46.59)	1.56 (0.03,88.33)	1.78 (0.03,117.57)	NA	0.12 (0.00,7.45))	**AMB**	
0.39 (0.05,3.04)	0.92 (0.13,6.48)	0.76 (0.06,9.54)	0.09 (0.01,1.23)	1.11 (0.15,8.31)	0.32 (0.04,2.79)	0.58 (0.09,3.52)	0.66 (0.05,8.31)	NA	**0.04 (0.00,0.51)**	0.37 (0.00,30.79)	**Polyene**

Legend: RR >1 means the treatment in top left is better. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; MICZ: miconazole; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

eFigure 6. Cluster Rank Combined the SUCRA

Legend: The y axis reports the SUCRA values as a percentage of "Withdrawal" . The x axis reports the IFI. Different colors identify the different clusters. AMB: conventional amphotericin B; AMBL: liposomal amphotericin B; KTCZ: ketoconazole; FLCZ: fluconazole; ITCZ: itraconazole; VOCZ: voriconazole; POCZ: posaconazole; CASP: caspofungin; MCFG: micafungin.

**eFigure 7.** Inconsistency Plot of All Outcomes

Panel A. Fungal Infections

| Loop	IF	95%CI (truncated)	Loop-specific Heterogeneity(τ^2)
08-10-12	1.40	(0.00,2.92)	0.000
01-08-12	1.33	(0.00,3.28)	0.036
01-03-06	1.15	(0.00,2.31)	0.000
07-08-11	0.98	(0.00,2.44)	0.000
07-08-10	0.97	(0.00,2.12)	0.000
04-07-10	0.95	(0.00,4.34)	0.000
01-07-09	0.92	(0.00,2.92)	0.179
01-04-10-12	0.67	(0.00,5.12)	0.659
01-07-08	0.63	(0.00,1.27)	0.112
01-08-09	0.63	(0.00,2.54)	0.000
01-04-08-10	0.57	(0.00,4.25)	0.344
07-08-12	0.41	(0.00,1.37)	0.000
01-03-08	0.41	(0.00,0.97)	0.006
07-08-09	0.37	(0.00,1.66)	0.000
01-07-12	0.29	(0.00,2.05)	0.144
03-07-08	0.15	(0.00,0.57)	0.000
01-04-07	0.10	(0.00,2.10)	0.247
01-03-07	0.06	(0.00,0.85)	0.134
07-10-12	0.05	(0.00,0.82)	0.000

Legend: Inconsistency plot assuming loop-specific heterogeneity estimates using the method of moments estimator. arm 01= placebo; arm 02= oral polyene; arm 03= conventional amphotericin B (AMB); arm 04= liposomal amphotericin B (AMBL); arm 05= miconazole (MICZ); arm 06= ketoconazole (KTCZ); arm 07= fluconazole (FLCZ); arm 08= itraconazole (ITCZ); arm 09= voriconazole (VOCZ); arm 10= posaconazole (POCZ); arm 11= caspofungin (CASP); arm 12= micafungin (MCFG).

Panel B. IFI

| Loop	IF	95%CI (truncated)	Loop-specific Heterogeneity(τ^2)
01-08-12	1.36	(0.00,3.11)	0.000
08-10-12	1.35	(0.00,3.30)	0.000
07-08-11	0.99	(0.00,2.45)	0.000
07-08-10	0.97	(0.00,2.12)	0.000
01-04-10-12	0.81	(0.00,5.05)	0.387
01-07-09	0.76	(0.00,3.05)	0.159
01-04-08-10	0.76	(0.00,4.13)	0.115
01-04-07	0.64	(0.00,2.94)	0.187
01-08-09	0.61	(0.00,2.53)	0.000
01-07-12	0.55	(0.00,2.47)	0.134
04-07-10	0.55	(0.00,4.02)	0.000
01-07-08	0.50	(0.00,1.15)	0.082
07-08-09	0.36	(0.00,1.66)	0.000
03-07-08	0.30	(0.00,0.75)	0.000
07-08-12	0.28	(0.00,1.34)	0.000
01-03-08	0.16	(0.00,0.78)	0.000
07-10-12	0.14	(0.00,1.66)	0.000
01-03-06	0.10	(0.00,2.27)	0.000
01-03-07	0.07	(0.00,0.99)	0.109

Legend: Inconsistency plot assuming loop-specific heterogeneity estimates using the method of moments estimator. arm 01= placebo; arm 02= oral polyene; arm 03= conventional amphotericin B (AMB); arm 04= liposomal amphotericin B (AMBL); arm 05= miconazole (MICZ); arm 06= ketoconazole (KTCZ); arm 07= fluconazole (FLCZ); arm 08= itraconazole (ITCZ); arm 09= voriconazole (VOCZ); arm 10= posaconazole (POCZ); arm 11= caspofungin (CASP); arm 12= micafungin (MCFG).

Panel C. Proven IFI

| Loop	IF	95%CI (truncated)	Loop-specific Heterogeneity(τ^2)
01-03-06	2.06	(0.00,4.52)	0.105
06-07-11	1.26	(0.00,4.66)	0.068
01-06-07	1.02	(0.03,2.02)	0.117
01-03-07	0.97	(0.00,3.30)	0.000
03-06-07	0.07	(0.00,1.05)	0.009

0 2 3 4 5

Legend: Inconsistency plot assuming loop-specific heterogeneity estimates using the method of moments estimator. arm 01= placebo; arm 02= oral polyene; arm 03= conventional amphotericin B (AMB); arm 04= liposomal amphotericin B (AMBL); arm 05= miconazole (MICZ); arm 06= ketoconazole (KTCZ); arm 07= fluconazole (FLCZ); arm 08= itraconazole (ITCZ); arm 09= voriconazole (VOCZ); arm 10= posaconazole (POCZ); arm 11= caspofungin (CASP); arm 12= micafungin (MCFG).

Panel D. Invasive Candidiasis

Loop		IF	95%CI (truncated)	Loop-specific Heterogeneity(τ^2)
01-03-07		2.53	(1.07,3.98)	0.000
01-03-08		1.11	(0.00,2.90)	0.000
07-08-12		0.99	(0.00,4.38)	0.000
01-07-08		0.98	(0.00,2.31)	0.000
03-07-08		0.44	(0.00,1.87)	0.000
07-08-11		0.38	(0.00,2.76)	0.000
01-04-07		0.28	(0.00,3.19)	0.000
07-08-10		0.11	(0.00,3.32)	0.000

0   2 3 4 5

Legend: Inconsistency plot assuming loop-specific heterogeneity estimates using the method of moments estimator. arm 01= placebo; arm 02= oral polyene; arm 03= conventional amphotericin B (AMB); arm 04= liposomal amphotericin B (AMBL); arm 05= miconazole (MICZ); arm 06= ketoconazole (KTCZ); arm 07= fluconazole (FLCZ); arm 08= itraconazole (ITCZ); arm 09= voriconazole (VOCZ); arm 10= posaconazole (POCZ); arm 11= caspofungin (CASP); arm 12= micafungin (MCFG).

Panel E. Invasive Aspergillus

Loop		IF	95%CI (truncated)	Loop-specific Heterogeneity(τ^2)
07-08-11		2.10	(0.00,4.97)	0.023
01-03-08		1.48	(0.00,4.02)	0.000
01-03-07		1.47	(0.00,3.55)	0.000
07-08-10		1.30	(0.00,3.37)	0.068
07-08-09		0.95	(0.00,3.37)	0.023
01-04-07		0.93	(0.00,5.20)	0.000
01-07-08		0.20	(0.00,1.42)	0.000
03-07-08		0.19	(0.00,2.63)	0.000
07-08-12		0.06	(0.00,3.62)	0.000

0 2 3 5 6

Legend: Inconsistency plot assuming loop-specific heterogeneity estimates using the method of moments estimator. arm 01= placebo; arm 02= oral polyene; arm 03= conventional amphotericin B (AMB); arm 04= liposomal amphotericin B (AMBL); arm 05= miconazole (MICZ); arm 06= ketoconazole (KTCZ); arm 07= fluconazole (FLCZ); arm 08= itraconazole (ITCZ); arm 09= voriconazole (VOCZ); arm 10= posaconazole (POCZ); arm 11= caspofungin (CASP); arm 12= micafungin (MCFG).

Panel F. Mortality

Loop	IF	95%CI (truncated)	Loop-specific Heterogeneity(τ^2)
01-07-12	1.71	(0.00,4.73)	0.065
08-10-12	1.62	(0.00,5.19)	0.000
07-10-12	1.29	(0.00,2.91)	0.000
01-08-09	1.14	(0.00,4.16)	0.000
01-08-12	1.07	(0.00,5.39)	0.000
01-07-09	0.98	(0.00,4.10)	0.107
01-03-06	0.87	(0.00,4.48)	0.383
07-08-12	0.60	(0.00,3.84)	0.000
01-04-07	0.40	(0.00,1.97)	0.143
07-08-10	0.30	(0.00,0.85)	0.000
07-08-09	0.20	(0.00,0.84)	0.000
03-07-08	0.19	(0.00,0.80)	0.000
01-03-08	0.14	(0.00,1.05)	0.043
01-07-08	0.08	(0.00,0.59)	0.000
01-03-07	0.01	(0.00,0.82)	0.083

Legend: Inconsistency plot assuming loop-specific heterogeneity estimates using the method of moments estimator. arm 01= placebo; arm 02= oral polyene; arm 03= conventional amphotericin B (AMB); arm 04= liposomal amphotericin B (AMBL); arm 05= miconazole (MICZ); arm 06= ketoconazole (KTCZ); arm 07= fluconazole (FLCZ); arm 08= itraconazole (ITCZ); arm 09= voriconazole (VOCZ); arm 10= posaconazole (POCZ); arm 11= caspofungin (CASP); arm 12= micafungin (MCFG).

Panel G. Fungi-related death

Loop	IF	95%CI (truncated)	Loop-specific Heterogeneity(τ^2)
01-03-06	1.72	(0.00,5.82)	0.000
07-08-10	1.43	(0.11,2.76)	0.000
07-10-12	1.33	(0.00,4.66)	0.000
03-07-08	0.81	(0.00,2.55)	0.331
01-04-07	0.74	(0.00,3.90)	0.084
01-03-07	0.71	(0.00,2.07)	0.000
01-08-10-12	0.34	(0.00,5.21)	0.144
01-07-08	0.21	(0.00,1.77)	0.368
01-03-08	0.13	(0.00,1.71)	0.003
01-07-12	0.01	(0.00,3.46)	0.000

0 2 3 5 6

Legend: Inconsistency plot assuming loop-specific heterogeneity estimates using the method of moments estimator. arm 01= placebo; arm 02= oral polyene; arm 03= conventional amphotericin B (AMB); arm 04= liposomal amphotericin B (AMBL); arm 05= miconazole (MICZ); arm 06= ketoconazole (KTCZ); arm 07= fluconazole (FLCZ); arm 08= itraconazole (ITCZ); arm 09= voriconazole (VOCZ); arm 10= posaconazole (POCZ); arm 11= caspofungin (CASP); arm 12= micafungin (MCFG).

Panel H. Withdrawal

Loop	IF	95%CI (truncated)	Loop-specific Heterogeneity(τ^2)
01-04-06	1.93	(0.05,3.81)	0.000
06-07-08	1.44	(0.21,2.66)	0.142
03-06-07	1.24	(0.00,2.87)	0.169
01-03-06	0.86	(0.00,6.11)	1.025
06-07-11	0.29	(0.00,3.45)	0.068
01-03-07	0.25	(0.00,4.15)	0.000
01-06-07	0.16	(0.00,1.29)	0.057
04-06-09	0.13	(0.00,1.34)	0.000

0 2 4 67

Legend: Inconsistency plot assuming loop-specific heterogeneity estimates using the method of moments estimator. arm 01= placebo; arm 02= oral polyene; arm 03= conventional amphotericin B (AMB); arm 04= liposomal amphotericin B (AMBL); arm 05= miconazole (MICZ); arm 06= ketoconazole (KTCZ); arm 07= fluconazole (FLCZ); arm 08= itraconazole (ITCZ); arm 09= voriconazole (VOCZ); arm 10= posaconazole (POCZ); arm 11= caspofungin (CASP); arm 12= micafungin (MCFG).

**eFigure 8.** Funnel Plots of All Outcomes

Panel A. Fungal Infections

Legend: In the comparison-adjusted funnel plot, the horizontal axis shows the difference of each i-study estimate YiXY from the summary effect for the respective comparison (YiXY-μXY) while the vertical axis presents the measure of dispersion of YiXY, namely the standard error of the effect size. The red line shows the null hypothesis. Each point represents a direct comparison; different colors correspond to different comparisons. The dashed black line represents the 95% confidence interval. The horizontal line represents the regression line; the regression line demonstrates that no asymmetry is present. arm 01= placebo; arm 02= oral polyene; arm 03= conventional amphotericin B (AMB); arm 04= liposomal amphotericin B (AMBL); arm 05= miconazole (MICZ); arm 06= ketoconazole (KTCZ); arm 07= fluconazole (FLCZ); arm 08= itraconazole (ITCZ); arm 09= voriconazole (VOCZ); arm 10= posaconazole (POCZ); arm 11= caspofungin (CASP); arm 12= micafungin (MCFG).

Panel B. IFI

Legend: In the comparison-adjusted funnel plot, the horizontal axis shows the difference of each i-study estimate YiXY from the summary effect for the respective comparison (YiXY-μXY) while the vertical axis presents the measure of dispersion of YiXY, namely the standard error of the effect size. The red line shows the null hypothesis. Each point represents a direct comparison; different colors correspond to different comparisons. The dashed black line represents the 95% confidence interval. The horizontal line represents the regression line; the regression line demonstrates that no asymmetry is present. arm 01= placebo; arm 02= oral polyene; arm 03= conventional amphotericin B (AMB); arm 04= liposomal amphotericin B (AMBL); arm 05= miconazole (MICZ); arm 06= ketoconazole (KTCZ); arm 07= fluconazole (FLCZ); arm 08= itraconazole (ITCZ); arm 09= voriconazole (VOCZ); arm 10= posaconazole (POCZ); arm 11= caspofungin (CASP); arm 12= micafungin (MCFG).

Panel C. Proven IFI

Legend: In the comparison-adjusted funnel plot, the horizontal axis shows the difference of each i-study estimate YiXY from the summary effect for the respective comparison (YiXY-μXY) while the vertical axis presents the measure of dispersion of YiXY, namely the standard error of the effect size. The red line shows the null hypothesis. Each point represents a direct comparison; different colors correspond to different comparisons. The dashed black line represents the 95% confidence interval. The horizontal line represents the regression line; the regression line demonstrates that no asymmetry is present. arm 01= placebo; arm 02= oral polyene; arm 03= conventional amphotericin B (AMB); arm 04= liposomal amphotericin B (AMBL); arm 05= miconazole (MICZ); arm 06= ketoconazole (KTCZ); arm 07= fluconazole (FLCZ); arm 08= itraconazole (ITCZ); arm 09= voriconazole (VOCZ); arm 10= posaconazole (POCZ); arm 11= caspofungin (CASP); arm 12= micafungin (MCFG).

Panel D. Invasive Candidiasis

Legend: In the comparison-adjusted funnel plot, the horizontal axis shows the difference of each i-study estimate YiXY from the summary effect for the respective comparison (YiXY-μXY) while the vertical axis presents the measure of dispersion of YiXY, namely the standard error of the effect size. The red line shows the null hypothesis. Each point represents a direct comparison; different colors correspond to different comparisons. The dashed black line represents the 95% confidence interval. The horizontal line represents the regression line; the regression line demonstrates that no asymmetry is present. arm 01= placebo; arm 02= oral polyene; arm 03= conventional amphotericin B (AMB); arm 04= liposomal amphotericin B (AMBL); arm 05= miconazole (MICZ); arm 06= ketoconazole (KTCZ); arm 07= fluconazole (FLCZ); arm 08= itraconazole (ITCZ); arm 09= voriconazole (VOCZ); arm 10= posaconazole (POCZ); arm 11= caspofungin (CASP); arm 12= micafungin (MCFG).

Panel E. Invasive Aspergillus

Legend: In the comparison-adjusted funnel plot, the horizontal axis shows the difference of each i-study estimate YiXY from the summary effect for the respective comparison (YiXY-μXY) while the vertical axis presents the measure of dispersion of YiXY, namely the standard error of the effect size. The red line shows the null hypothesis. Each point represents a direct comparison; different colors correspond to different comparisons. The dashed black line represents the 95% confidence interval. The horizontal line represents the regression line; the regression line demonstrates that no asymmetry is present. arm 01= placebo; arm 02= oral polyene; arm 03= conventional amphotericin B (AMB); arm 04= liposomal amphotericin B (AMBL); arm 05= miconazole (MICZ); arm 06= ketoconazole (KTCZ); arm 07= fluconazole (FLCZ); arm 08= itraconazole (ITCZ); arm 09= voriconazole (VOCZ); arm 10= posaconazole (POCZ); arm 11= caspofungin (CASP); arm 12= micafungin (MCFG).

Panel F. Mortality

Legend: In the comparison-adjusted funnel plot, the horizontal axis shows the difference of each i-study estimate YiXY from the summary effect for the respective comparison (YiXY-μXY) while the vertical axis presents the measure of dispersion of YiXY, namely the standard error of the effect size. The red line shows the null hypothesis. Each point represents a direct comparison; different colors correspond to different comparisons. The dashed black line represents the 95% confidence interval. The horizontal line represents the regression line; the regression line demonstrates that no asymmetry is present. arm 01= placebo; arm 02= oral polyene; arm 03= conventional amphotericin B (AMB); arm 04= liposomal amphotericin B (AMBL); arm 05= miconazole (MICZ); arm 06= ketoconazole (KTCZ); arm 07= fluconazole (FLCZ); arm 08= itraconazole (ITCZ); arm 09= voriconazole (VOCZ); arm 10= posaconazole (POCZ); arm 11= caspofungin (CASP); arm 12= micafungin (MCFG).

Panel G. Fungi-related death

Legend: In the comparison-adjusted funnel plot, the horizontal axis shows the difference of each i-study estimate YiXY from the summary effect for the respective comparison (YiXY-μXY) while the vertical axis presents the measure of dispersion of YiXY, namely the standard error of the effect size. The red line shows the null hypothesis. Each point represents a direct comparison; different colors correspond to different comparisons. The dashed black line represents the 95% confidence interval. The horizontal line represents the regression line; the regression line demonstrates that no asymmetry is present. arm 01= placebo; arm 02= oral polyene; arm 03= conventional amphotericin B (AMB); arm 04= liposomal amphotericin B (AMBL); arm 05= miconazole (MICZ); arm 06= ketoconazole (KTCZ); arm 07= fluconazole (FLCZ); arm 08= itraconazole (ITCZ); arm 09= voriconazole (VOCZ); arm 10= posaconazole (POCZ); arm 11= caspofungin (CASP); arm 12= micafungin (MCFG).

Panel H. Withdrawal

Legend: In the comparison-adjusted funnel plot, the horizontal axis shows the difference of each i-study estimate YiXY from the summary effect for the respective comparison (YiXY-μXY) while the vertical axis presents the measure of dispersion of YiXY, namely the standard error of the effect size. The red line shows the null hypothesis. Each point represents a direct comparison; different colors correspond to different comparisons. The dashed black line represents the 95% confidence interval. The horizontal line represents the regression line; the regression line demonstrates that no asymmetry is present. arm 01= placebo; arm 02= oral polyene; arm 03= conventional amphotericin B (AMB); arm 04= liposomal amphotericin B (AMBL); arm 05= miconazole (MICZ); arm 06= ketoconazole (KTCZ); arm 07= fluconazole (FLCZ); arm 08= itraconazole (ITCZ); arm 09= voriconazole (VOCZ); arm 10= posaconazole (POCZ); arm 11= caspofungin (CASP); arm 12= micafungin (MCFG).